Evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Adult Volunteers According to Increasing Insulin Resistance and Loss of Glucose Control.

Science

First published in Current Research in Diabetes & Obesity Journal on 2022 January.
Curre Res Diabetes & Obes J 2022; 15(3): 555914. DOI: 10.19080/CRDOJ.2022.15.555914

Authors: Forst T, Botz I, Berse M, Voswinkel S, Strempler ME, Baumann S, Schultz A

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Adult Volunteers According to Increasing Insulin Resistance and Loss of Glucose Control.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.